Journal article icon

Journal article

SPiRIT study protocol (Shoulder Pain: Randomised trial of Injectable Treatments): a randomised feasibility and pilot study of autologous protein solution (APS) vs corticosteroids for treating subacromial shoulder pain

Abstract:
Background The management of subacromial shoulder pain represents a significant challenge and is typically managed through either physiotherapy, joint injection or surgical intervention. Recent surgical trials have questioned the efficacy and there is a need to improve the evidence base for the non-surgical management of this condition. The study aims to provide evidence of the feasibility of conducting a randomised controlled trial to compare the efficacy of autologous protein solution (APS) against the current standard of care, corticosteroid injection (CSI) for subacromial shoulder pain. Autologous protein solution (APS) is a blood-derived biological injection which has been shown to have anti-inflammatory effects. Methods A parallel-group two-arm randomised control trial will be conducted, comparing APS and CSI for shoulder pain. Fifty patients will be recruited. Feasibility will be assessed by examination of the conversion rate of eligible participants to the total number of participants recruited, whether it is possible to collect the appropriate outcome measures and the levels of retention/data compliance at follow-up dates. Discussion CSI is the mainstay of conservative management of subacromial shoulder pain. Trials and systematic reviews have reported differing conclusions, but the consensus view is that any benefits seen from CSI use are most likely to be short-term and there remains a significant number of patients who go on to have surgical intervention despite CSI. Biological injections, such as APS are being increasingly used, in the anticipation they may offer improved longer lasting outcomes for shoulder pain. However, the evidence to demonstrate the comparative efficacy of CSI versus APS does not currently exist. If feasible, a fully powered study will offer clarity to the treatment pathway of thousands of patients each year with subacromial pain
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1186/s40814-023-01425-9
Publication website:
https://eprints.whiterose.ac.uk/208760/1/s40814-023-01425-9.pdf

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Kadoorie Centre
Role:
Author
ORCID:
0000-0001-7746-1268
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Kadoorie Centre
Role:
Author
ORCID:
0009-0001-4878-5463
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Kadoorie Centre
Role:
Author
ORCID:
0000-0003-3464-3867
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Kadoorie Centre
Role:
Author
ORCID:
0000-0002-8857-5743
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Kadoorie Centre
Role:
Author
ORCID:
0000-0003-1493-0391


More from this funder
Funder identifier:
10.13039/501100009128


Publisher:
BioMed Central
Journal:
Pilot and Feasibility Studies More from this journal
Volume:
10
Issue:
1
Pages:
9-9
Article number:
9
Publication date:
2024-01-17
DOI:
EISSN:
2055-5784
ISSN:
2055-5784


Language:
English
Keywords:
Pubs id:
1606111
Local pid:
pubs:1606111
Source identifiers:
W4390952855
Deposit date:
2026-06-05
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP